Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey

Journal of Dermatology

Volumn 39, Issue 5, 2012, Pages 439-442

  Büyüköztürk, Suna ^a   Gelincik, Asli ^a   Demirtürk, Mustafa ^a   Kocaturk, Emek ^b   Çolakoǧlu, Bahattin ^a   Dal, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Angioedema; Chronic urticaria; Hives; Omalizumab; Quality of life

Indexed keywords

OMALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; QUALITY OF LIFE; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANGIOEDEMA; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHRONIC DISEASE; DATA COLLECTION; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; QUALITY OF LIFE; URTICARIA;

EID: 84859799340     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01473.x     Document Type: Article

References (21)

1. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI ? GA(2)LEN ? EDF ? WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI ? GA(2)LEN ? EDF ? WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
3. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695.
4. Spector SL, Tan RA. Effects of omalizumab on patients with chronic urticaria. Ann Allery Asthma Immunol 2007; 99: 190-193. (Pubitemid 47264781)
5. Sands MF, Blume JW, Schwartz SA. Succesful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007; 120: 979-981. (Pubitemid 47534214)
6. Kaplan AP, Joseph K, Maykut RJ, Geba ZP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 659-673.
7. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab- an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66: 298-305.
8. Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777-780.
9. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60 (8): 1073-1078. (Pubitemid 40942764)
10. Kocatürk E, Aktaş S, Kavala M, et al. The Turkish Version of the chronic urticaria quality-of-life questionnaire: cultural adaptation, assessment of reliability and validity. Acta Derm Venereol 2011. doi: 10.2340/00015555-1199.
11. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2) LEN task force report (1). Allergy 2011; 66: 317-330.
12. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136 (2): 197-201. (Pubitemid 27062719)
13. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58 (7): 621-623. (Pubitemid 36831317)
14. Lennox RD, Leahy MJ. Validation of the dermatology life quality index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93 (2): 142-146. (Pubitemid 39128493)
15. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152 (2): 289-295. (Pubitemid 40343600)
16. Gober LM, Sterba PM, Eckman JA, Saini SS. Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients. J Allergy Clin Immunol 2008; 121 (Suppl 1): S147.
17. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with Omalizumab. Acta Derm Venereol 2010; 90: 443-444.
18. MaurerM, Altrichter S, Bieber T et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128 (1): 202-209.
19. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008; 146 (1): 66-70. (Pubitemid 351562944)
20. Iemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010; 20 (3): 252-254.
21. Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 2011; 9 (1): 2.